scholarly journals Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58

Diabetes Care ◽  
2022 ◽  
Author(s):  
Ahmed A. Kolkailah ◽  
Stephen D. Wiviott ◽  
Itamar Raz ◽  
Sabina A. Murphy ◽  
Ofri Mosenzon ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
High Cardiovascular Risk

scholarly journals Clinical profiles and quality of care of subjects with type 2 diabetes according to their cardiovascular risk: an observational, retrospective study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Basilio Pintaudi ◽  
Alessia Scatena ◽  
Gabriella Piscitelli ◽  
Vera Frison ◽  
Salvatore Corrao ◽  
...  
Keyword(s):  
Risk Factors ◽  
Type 2 Diabetes ◽  
Quality Of Care ◽  
Cardiovascular Risk ◽  
High Risk ◽  
Cardiovascular Risk Factors ◽  
High Cardiovascular Risk ◽  
Very High

Abstract Background The European Society of Cardiology (ESC) recently defined cardiovascular risk classes for subjects with diabetes. Aim of this study was to explore the distribution of subjects with type 2 diabetes (T2D) by cardiovascular risk groups according to the ESC classification and to describe the quality indicators of care, with particular regard to cardiovascular risk factors. Methods The study is based on data extracted from electronic medical records of patients treated at the 258 Italian diabetes centers participating in the AMD Annals initiative. Patients with T2D were stratified by cardiovascular risk. General descriptive indicators, measures of intermediate outcomes, intensity/appropriateness of pharmacological treatment for diabetes and cardiovascular risk factors, presence of other complications and overall quality of care were evaluated. Results Overall, 473,740 subjects with type 2 diabetes (78.5% at very high cardiovascular risk, 20.9% at high risk and 0.6% at moderate risk) were evaluated. Among people with T2D at very high risk: 26.4% had retinopathy, 39.5% had albuminuria, 18.7% had a previous major cardiovascular event, 39.0% had organ damage, 89.1% had three or more risk factors. The use of DPP4-i markedly increased as cardiovascular risk increased. The prescription of secretagogues also increased and that of GLP1-RAs tended to increase. The use of SGLT2-i was still limited, and only slightly higher in subjects with very high cardiovascular risk. The overall quality of care, as summarized by the Q score, tended to be lower as the level of cardiovascular risk increased. Conclusions A large proportion of subjects with T2D is at high or very high risk. Glucose-lowering drug therapies seem not to be adequately used with respect to their potential advantages in terms of cardiovascular risk reduction. Several actions are necessary to improve the quality of care.

scholarly journals Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile

Rheumatology ◽  
2008 ◽  
Vol 47 (10) ◽  
pp. 1567-1570 ◽  
Author(s):  
H. K. Choi ◽  
M. A. De Vera ◽  
E. Krishnan
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
Risk Profile ◽  
Cardiovascular Risk Profile ◽  
High Cardiovascular Risk

scholarly journals Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes

2020 ◽  
Vol 66 (9) ◽  
pp. 1283-1288
Author(s):  
Eduardo Bello Martins ◽  
Eduardo Gomes Lima ◽  
Fábio Grunspun Pitta ◽  
Leticia Neves Solon Carvalho ◽  
Thiago Dias de Queiroz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Pharmacological Therapy ◽  
High Cardiovascular Risk ◽  
Cardiovascular Risk Reduction ◽  
Drug Classes ◽  
Clinical Benefits

SUMMARY The pharmacological therapy for type 2 diabetes mellitus has presented important advances in recent years, which has impacted the treatment of patients with established cardiovascular disease or with high cardiovascular risk. In this scenario, two drug classes have emerged and demonstrated clear clinical benefits: SGLT-2 inhibitors and GLP-1 agonists. The present review discusses the pharmacology, adverse effects, and clinical trials that have demonstrated the benefits of these medications in reducing cardiovascular risk.

scholarly journals Association of galectin-3 with high cardiovascular risk in patients with type 2 diabetes attending a multi-specialty hospital in South India

2016 ◽  
pp. 5417-5421
Author(s):  
Damal Sriram ◽  
Govindaraj Gowri ◽  
Sujithera Haridoss ◽  
Surendran Venkatesan ◽  
Ilayaraja Rajendran ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
South India ◽  
High Cardiovascular Risk ◽  
Specialty Hospital ◽  
Galectin 3

Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: A randomized, double-blind, placebo-controlled study (Omega-FMD)

2018 ◽  
Vol 271 ◽  
pp. 148-155 ◽  
Author(s):  
Aleksander Siniarski ◽  
Maciej Haberka ◽  
Magdalena Mostowik ◽  
Renata Gołębiowska-Wiatrak ◽  
Małgorzata Poręba ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Fatty Acids ◽  
Cardiovascular Risk ◽  
Controlled Study ◽  
Omega 3 ◽  
High Cardiovascular Risk ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Very High

Tirzepatide Tested for Type 2 Diabetes With High Cardiovascular Risk

JAMA ◽  
2021 ◽  
Vol 326 (24) ◽  
pp. 2464
Author(s):  
Anita Slomski
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Risk ◽  
High Cardiovascular Risk
Sign in / Sign up

Export Citation Format

Share Document